Applied DNA Sciences Rebrands as BNB-Focused Digital Asset Company, Partners with B2i Digital for Investor Outreach

Applied DNA Sciences, Inc. has been named a B2i Digital Featured Company as it completes a strategic rebrand reflecting its expansion from nucleic acid manufacturing to a broader platform integrating digital asset management. The biotechnology company, which trades under the new ticker symbol "BNBX" on NASDAQ, is implementing a yield-focused BNB digital asset treasury strategy designed to enhance shareholder value while continuing to leverage its proprietary nucleic acid production expertise.

The company's transformation represents a significant shift in corporate strategy, moving beyond its traditional biotechnology focus to embrace digital asset management as a core component of its business model. David Shapiro, CEO of B2i Digital, stated that Applied DNA's shift toward a BNB-centric digital asset treasury underscores its commitment to innovation in corporate finance and shareholder alignment. This rebrand signals a strategic move toward greater capital efficiency and digital integration within the corporate structure.

Applied DNA previously announced approximately $27 million in aggregate gross proceeds to implement its BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC and a five-year Strategic Advisor Agreement with Cypress Management LLC. The company changed its ticker from "APDN" to "BNBX" effective October 7, 2025, directly reflecting its new digital asset treasury strategy and providing market participants with clear indication of its strategic direction.

Clay Shorrock, CEO of Applied DNA Sciences, emphasized that partnering with B2i Digital enables the company to share its transformation and long-term vision with a much wider investor audience. As the company executes on its BNB treasury strategy, this collaboration will help investors understand how the approach to digital asset management supports both growth and balance-sheet strength. The partnership provides access to B2i Digital's network of over 1.4 million market participants through platforms including LinkedIn, X, and Facebook.

Through its LineaRx subsidiary, Applied DNA continues to commercialize its LineaDNA™, LineaRNAP™, and LineaIVT™ platforms, which enable cell-free manufacturing of DNA and RNA for therapeutics and diagnostics. This dual approach is designed to generate yield and token accumulation within the Binance ecosystem while maintaining a foundation of operational technology expertise. The company maintains its corporate presence at adnas.com while expanding its digital footprint.

As a B2i Digital Featured Company, Applied DNA will be introduced to retail and institutional investors across B2i Digital's multi-channel network, which also includes Instagram, YouTube, Threads, Reddit, and Stocktwits. The campaign will feature dedicated digital content, investor presentations, and company updates designed to highlight Applied DNA's strategic transformation and communicate its evolving growth narrative at scale. B2i Digital's platform can be accessed through their main website at b2idigital.com.

The strategic pivot represents a notable example of traditional biotechnology companies exploring digital asset integration as part of corporate treasury management. Applied DNA's approach combines its established expertise in nucleic acid production with emerging digital asset strategies, creating a hybrid business model that could influence how other companies in the sector approach capital allocation and shareholder value creation. This transformation occurs amid growing corporate interest in digital assets as alternative treasury instruments and reflects broader trends in corporate finance innovation.